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Objective: To discover the effect of partial splenic embolization on the immune function
of cirrhotic patients with hypersplenism.
Methods: Patients involved in the study were enrolled and divided into three groups,
including control group, experimental group, and complication group. Numbers of CD3+,
CD4+ and CD8+ T cells and CD4+CD25+CDl27low/− Treg cells in the peripheral blood of
patients before surgery, 1 month, 6 months, 1 year, and 2 years after surgery were
analyzed by ﬂuorescence active cell sorting (FACS). Contents of immunoglobulins (IgA,
IgG and IgM) were analyzed by auto immunoassay analyzer.
Results: In the peripheral blood of patients from experimental group, numbers of CD3+,
CD4+ and CD8+ T cells initially declined, but afterwards increased to normal level; in the
peripheral blood of patients from complication group, CD3+ and CD8+ T cells showed the
same trend, but the number of CD4+ T cells was below normal level at all detection times.
Furthermore, CD3+, CD4+ and CD8+ T cells in the peripheral blood of patients from
complication group were initially less than those in experimental group, and afterwards
were comparable between two groups. In patients from both experimental group and
complication group, the number of CD4+ CD25+ CDl27low/−Treg cells increased 1 month
and 6 months after surgery, and gradually restored to normal level.
CD4+CD25+CDl27low/− Treg cell counts in patients from complication group were
initially more than those in patients from experimental group 1 month and 6 months after
surgery, but then they were comparable. Furthermore, contents of immunoglobulins (IgA,
IgG and IgM) were comparable in three groups at all detection times.
Conclusion: Partial splenic embolization inﬂuenced the immune function of cirrhotic
patients with hypersplenism in the short term but the immune function could afterwards
gradually restore to normal. Our results implicated that measures that prevent infection
and improve immune function were necessary in early stage after undergoing PSE in
order to reduce complications.1. Introduction
Chronic viral hepatitis B is a common disease in China, the
morbidity of which is 8%–10%. Patients with hepatitis B usually
develop hypersplenism in the period of liver cirrhosis decom-
pensation. Hypersplenism is clinically characterized as decline
of hemocytoes, such as white blood cells, red blood cells, andplatelet, which can result in gastrointestinal bleeding, anemia,
and infection. As the development of interventional techniques,
partial splenic embolization (PSE) with advantages of smaller
trauma and partial spleen-conserving has been widely applied in
clinic to replace splenectomy.
PSE, however, has been proved to cause some complications,
such as peritoneal cavity infection, intractable abdominal cavity
effusion, intestine ﬂatulence, splenic abscess, and also portal
vein and mesenteric arterial thrombosis, which can even lead to
death [1–3]. Additionally, the effect of PSE on the immune
function of patients has been a hot topic of academic research.
However, there is still no uniﬁed evaluation criterion of spleenrticle under the CC BY-NC-ND license (http://
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mechanism of which has not been fully elucidated.
Here, to uncover the relevance between PSE, postoperative
complications and immune function, CD3+, CD4+ and CD8+ T
cells, CD4+CD25+CDl27low/− Treg cells (regulatory T cell,
Treg), and contents of immunoglobulins (including IgA, IgG
and IgM) in the peripheral blood of cirrhotic patients with
hypersplenism were analyzed.
2. Materials and methods
2.1. Patients
The study was approved by the Ethics Committee of the
authors' afﬁliation prior to initiation. Patients have been
informed and signed the informed consent before blood draw-
ing. Patients involved in this study were enrolled and divided
into three groups: control group (healthy population), experi-
mental group (patients without complications after PSE), and
complication group (patients with complications after PSE).
Symptoms of hepatitis B cirrhotic and hypersplenism were
diagnosed according to clinic history, virus immunology ex-
amination, liver tests, peripheral hemogram test, and imageo-
logical examination. A total of 50 persons, including 33 males
and 17 females, who were physically healthy, were enrolled as
the control group (age range: 45–68 years, mean age: 56.2
years). The experimental group was consists of 57 cases,
including 38 males and 19 females (age range: 41–64 years,
mean age: 52.6 years). The complication group had 51 cases,
including 37 males and 14 females (age range: 50–68 years,
mean age: 57.3 years).
2.2. Partial splenic embolization
Partial splenic embolization (PSE) was operated as follows.
The participants were asked to fast for 12 h and not to drink for
6 h before undergoing the surgery. Seldinger puncture, com-
bined with digital subtracting X-ray system, were applied to
right arteriopuncture to reach carotid sheath. Catheter (Yashiro)
was guided by guide wire to spleen artery to monitor spleno-
megalia. We also measured the size of spleen during operation.
Area of embolism was subsequently calculated according to
projected area and preoperative hemogram indexes. The area of
embolism was accounted for about 1/3 to 1/2 of total spleen
area. Spleen was perfused with gentamicin (1.6 × 105 units) and
embolized using gelatin sponge particles (diameter: 150–
350 mm) to retard bloodstream. Spleen artery radiography was
operated to monitor range and degree of embolism. If necessary,
re-embolism was conducted in case of insufﬁcient embolism or
excessive embolism.
2.3. Fluorescence active cell sorting (FACS) analysis
Draw peripheral blood from patients was conducted 1 day
before PSE, 6 months, 1 year, and 2 year after PSE, respectively.
CD3+, CD4+ and CD8+ T cells and CD4+ CD25+CDl27low/−
Treg cells in patients' peripheral blood were analyzed by FACS.
Three repeats of each peripheral blood sample were labeled with
anti-CD4-PE, anti-CD4-PE/anti-CD25 FITC, anti-CDl27, and
anti-CD3-PE/anti-CD8-FITC antibodies, respectively. Add
100 mL anticoagulant whole blood and incubate in dark for25 min. Then, 2 mL lysis buffer was added in each samples and
incubated in dark for 15 min. After red blood cells hemolysis,
samples were centrifuged at a speed of 200 g for 5 min and
washed with PBS three times in the same way. Pallets were
resuspended in 200 mL 1% paraformaldehyde (PFA) and
analyzed by FACS.
2.4. Analysis of immunoglobulins
Immunoglobulins (IgA, IgM and IgG) in patients' peripheral
blood, drawn 1 day before PSE, 6 months, 1 year and 2 years
after PSE, were analyzed by auto immunoassay analyzer,
respectively.
2.5. Statistical analysis
All statistical analyses were performed using SPSS 16.0
software. Data were presented as Mean ± SD. For each group,
data from different detection times were tested by repetitive
measurement ANOVA. For the same detection times, data from
different groups were tested by one-way ANOVA. Dunnett-t test
was used for analyzing variation between two groups. P < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. FACS analysis
3.1.1. CD3+ T cells in peripheral blood
CD3+ T cells in the peripheral blood of patients from
complication group were less than those in control group form
pre-PSE to post-PSE (P < 0.05). Numbers between two groups
were comparable 2 years after PSE (P > 0.05). 1 year and 2
years after PSE, numbers of CD3+ T cells in patients from
complication group were not signiﬁcantly different from those
before PSE (P > 0.05).
CD3+ T cells in the peripheral blood of patients from
experimental group were less than that in control group from
pre-PSE to 6 months after PSE (P < 0.05). The numbers be-
tween two groups were comparable one year later (P > 0.05). 1
month after PSE, the number of CD3+ T cells dramatically
declined (P < 0.05). However, 6 months after PSE, it increased
to normal level and maintained to 2 years after PSE.
1 month, 6 months and 1 year after PSE, CD3+ T cells in
complication group were less than those in experimental group
(P < 0.05). Then, they increased to the level of experimental
group 2 years after PSE (P > 0.05) (Table 1).
3.1.2. CD4+ T cells in peripheral blood
CD4+ T cells in the peripheral blood of patients from both
complication group and experimental group were less than those
in control group (P < 0.05). 1 month, 6 months and 1 year after
PSE, CD3+ T cells of complication group and experimental
group were less than those pre-PSE (P < 0.05). The signiﬁcant
difference disappeared until 2 years after PSE. 1 month after
PSE, the number of CD4+ T cells in the peripheral blood of
patients from experimental group was lower than preoperative
level (P < 0.05). However, it increased to the preoperative level
6 months after PSE, and maintained to 2 years after PSE. 6
months after PSE, CD4+ T cells in the peripheral blood of pa-
tients from complication group were less than those in
Table 1
CD3+, CD4+ and CD8+ T cells at different detection times in each group (%).
Groups Pre-operation After PSE
1 month 6 months 12 months 24 months
Control group CD3+ 74.55 ± 6.24 74.14 ± 7.21 72.20 ± 5.78 70.88 ± 6.78 75.46 ± 7.22
CD4+ 44.24 ± 5.12 40.21 ± 5.21 42.22 ± 4.88 44.83 ± 4.78 45.16 ± 4.22
CD8+ 40.45 ± 4.72 39.34 ± 5.11 41.34 ± 4.79 38.88 ± 4.88 44.12 ± 5.28
Experimental group CD3+ 60.21 ± 5.23* 43.56 ± 4.87*#: 50.14 ± 5.45*: 64.86 ± 4.34: 65.36 ± 7.16
CD4+ 32.24 ± 4.65* 23.52 ± 3.87*# 34.14 ± 3.75*: 31.56 ± 4.14* 33.26 ± 4.18*
CD8+ 30.14 ± 3.90* 27.82 ± 4.17*,: 31.21 ± 3.76* 30.56 ± 4.12* 37.86 ± 4.58#
Complication group CD3+ 58.43 ± 6.11* 33.36 ± 4.44*,# 35.58 ± 4.21*# 51.58 ± 7.12* 67.18 ± 6.78
CD4+ 34.46 ± 5.11* 25.46 ± 4.14*,# 23.28 ± 4.01*# 26.34 ± 4.12*# 35.08 ± 4.88*
CD8+ 28.58 ± 4.02* 18.87 ± 3.34*,# 25.28 ± 4.21* 31.43 ± 4.41* 42.14 ± 4.08#
Note: Data were presented as mean ± SD. *P < 0.05 (compared with control group), #P < 0.05 (compared with pre-operation), :P < 0.05 (compared
with complication group).
Table 2
CD4+, CD25+, CDl27low/− Treg cells at different detection times in each group.
Groups Pre-operation After PSE
1 month 6 months 12 months 24 months
Control group 2.55 ± 0.62 2.34 ± 0.61 2.64 ± 0.79 2.88 ± 1.05 2.52 ± 0.58
Experimental group 4.48 ± 1.11* 8.02 ± 1.17*#: 4.21 ± 1.06: 3.86 ± 1.22 4.07 ± 1.08
Complication group 5.75 ± 0.94* 10.85 ± 1.44*# 9.12 ± 1.21*# 3.13 ± 1.11 3.24 ± 1.08
Note: Data were presented as mean ± SD. *P < 0.05 (compared with control group), #P < 0.05 (compared with pre-operation), :P < 0.05 (compared
with complication group).
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niﬁcant differences between two groups at other detection times
after PSE (Table 1).
3.1.3. CD8+ T cells in peripheral blood
From pre-PSE to 1 year after PSE, CD8+ T cells in the pe-
ripheral blood of patients from complication group were less
than those in control group (P < 0.05), and it increased to
normal level 2 years after PSE. 1 month and 2 years after PSE,
numbers of CD8+ T cells in complication group were lower than
preoperative level (P < 0.05), and showed no signiﬁcance at
other detection times after PSE.
1 month and 1 year after PSE, CD8+ T cells in experimental
group were less than those in control group (P < 0.05), but were
comparable with those pre-PSE. However, 2 years after PSE,
CD8+ T cells in experimental group were much more than those
pre-PSE (P < 0.05).
1 month after PSE, the number of CD8+ T cells in compli-
cation group was lower than that in experimental groupTable 3
Contents of IgA, IgG and IgM at different detection times in each group (g/
Groups Pre-operation
1 mon
Control group IgA 2.54 ± 0.92 2.33 ±
IgG 14.52 ± 1.94 16.23 ±
IgM 1.65 ± 0.72 1.73 ±
Experimental group IgA 3.34 ± 1.12 3.02 ±
IgG 15.47 ± 2.11 16.02 ±
IgM 2.04 ± 0.82 2.02 ±
Complication group IgA 3.45 ± 1.04 3.25 ±
IgG 16.45 ± 1.54* 13.35 ±
IgM 2.15 ± 0.90 1.85 ±
Note: Data were presented as mean ± SD.(P < 0.05), but it was comparable between two groups at other
detection times after PSE (Table 1).
3.1.4. CD4+CD25+CDl27low/− Treg cells in peripheral
blood
1 month and 6 months after PSE, CD4+CD25+CDl27low/−
Treg cells in the peripheral blood of patients from complication
group were much more than those pre-PSE and in control group
(P < 0.05). However, signiﬁcant differences disappeared at
following postoperative visit.
1 month after PSE, CD4+CD25+CDl27low/− Treg cells in
experimental group were much more than those pre-PSE and in
control group (P < 0.05). However, numbers were comparable
from 6 months to 2 years after PSE.
1 month and 6 months after PSE, the number of
CD4+CD25+CDl27low/− Treg cells in complication group was
much higher than postoperative level of control group
(P < 0.05). From then on, numbers were comparable in two
groups at other detection times after PSE (Table 2).L).
After PSE
th 6 months 12 months 24 months
0.62 2.74 ± 0.89 15.27 ± 1.94 2.32 ± 0.78
1.62 14.74 ± 1.89 15.27 ± 1.94 15.12 ± 1.66
0.81 1.94 ± 0.81 1.67 ± 0.91 2.02 ± 0.84
1.07 2.21 ± 0.86 2.86 ± 0.82 3.07 ± 1.03
2.05 14.41 ± 1.76 14.81 ± 1.77 13.57 ± 2.01
0.72 1.88 ± 0.85 2.15 ± 0.81 2.07 ± 0.73
0.84 1.92 ± 0.81 2.13 ± 0.91 2.24 ± 1.02
1.84 14.90 ± 1.82 15.18 ± 1.93 14.45 ± 2.06
0.81 1.68 ± 0.78 1.83 ± 0.68 2.04 ± 0.82
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Contents of IgA, IgG and IgM in the peripheral blood of
patients from complication group were comparable with those
pre-PSE and in control group (P > 0.05).
From 1 year to 2 years after PSE, contents of IgA in
experimental group were comparable with those pre-PSE and in
control group (P > 0.05).
Contents of IgA in complication group were also comparable
with those in experimental group at all detection times after PSE
(P > 0.05) (Table 3).
4. Discussion
Pathological change of chronic viral hepatitis B cirrhosis is a
complicated process, having a tremendous impact on the func-
tion of various systems of the body. Also, the immune function,
particularly the cellular immune function, of patients with
cirrhosis is badly affected. Cirrhosis can result in signiﬁcant
elevation of venous pressure, spleen ecchymosis, blood ﬂow
stasis, and cell hypoxia, leading to functional and morphological
alterations of immunocytes, signiﬁcant decrease of T and B
cells, and decline of immune function [4]. Cirrhosis patients with
hypersplenism suffer from numerous severe clinical conditions,
such as immunodeﬁciency and coagulation defects, which result
in infection, bleeding, even liver and multiple organ failure [5].
Meanwhile, increase of splenic vein ﬂow volume (SVFV) in
turn leads to an elevation of portal venous pressure. Thus,
most of cirrhosis patients with hypersplenism suffer
esophageal and gastric varices, and even rupture hemorrhage,
which endanger their lives.
However, therapies of hepatitis B cirrhosis and hyper-
splenism are controversial about whether spleen can be
conserved [6]. Spleen is a signiﬁcant organ for body and 25% of
the total lymphocytes are processed through it. Spleen with
various functions, such as immunity, hemopoiesis, blood
storage, and endocrine, is one of important components of
immune-nerve-endocrine system. Among these, immune func-
tion is considered as one of most important functions of spleen
[7,8].
As the development of interventional medicine, partial
splenic embolization (PSE) has been widely applied in clinical
treatment of hypersplenism. Compared with traditional therapy,
PSE has fewer surgical risks, smaller trauma, shorter hospital
stays, and better clinical effects. Moreover, PSE can conserve
partial spleen, which is critical to the basic immune function of
patients. Thus, it is also referred to as functional splenectomy
and is accepted by doctors and patients.
Cluster differentiation (CD) molecules are speciﬁc bio-
markers on surface of lymphocytes [9,10]. CD+ cells play
important roles in immune response. Nowadays, studies of
immune function of spleen in patients with hypersplenism
mainly focus on the number of CD+ T cells and immune
factors secreted by lymphocytes. The relevance between
subsets of T cells (e.g. Treg cells) and immune function of
spleen in patients with hypersplenism has been well studied
[11]. CD4+CD25+ Treg cells are characteristic of immune
anergy and immunosuppression. Immunosuppression is
deﬁned as repression of activation and proliferation of CD4+
and CD8+ T cells when CD4+CD25+ Treg cells are activated
by some signal pathways [12,13]. It has been reported that
activated CD4+, CD25+ Treg cells highly expressed CD127(CD4+CD25+CDl27high), while CD4+, CD25+ Treg cells with
active effect slightly expressed CD127 (CD4+CD25+CDl27low/
−). Therefore, CD4+CD25+CDl27low/− can be used as the
deﬁnitive biomarker of natural Treg cells [14–16]. Researchers
have demonstrated that patients with hypersplenism have more
CD4+CD25+CDl27low/− Treg cells than normal people [17].
Moreover, the number of CD4+CD25+CDl27low/− Treg cells
has a negative relation with that of CD3+ and CD4+ T cells in
patients [17], which may be a result of T cells proliferation
repressed by CD4+CD25+CDl27low/− Treg cells.
In this study, CD3+, CD4+ and CD8+ T cells, and
CD4+CD25+ Treg cells, as well as expression of IgA, IgG and
IgM, in peripheral blood of patients were analyzed. We
discovered that numbers of CD3+ and CD8+ T cells in patients
from complication group was initially lower than that in control
group, and afterwards increased to normal level. However,
CD4+ T cells in complication group were less than those in
control group all the time. After PSE, numbers of CD3+, CD4+
and CD8+ T cells in patients from complication group initially
decreased, but afterwards increased to normal level compared
with those pre-PSE. In the peripheral blood of patients from
experimental group, numbers of CD3+, CD4+ and CD8+ T cells
were initially lower than normal level at early stage of post-PSE,
and afterwards increased to normal level. CD3+ and CD4+ T
cells after PSE had a similar trend compared with pre-operation.
However, the number of CD8+ T cells after PSE was comparable
with that pre-PSE. Moreover, in the peripheral blood of patients
from complication group, numbers of CD3+, CD4+ and CD8+ T
cells in early stage of post-PSE were lower than those in
experimental group, but they were similar in late stage. In pa-
tients form both experimental group and complication group,
CD4+CD25+CDl27low/− Treg cells initially increased 1 month
and 6 months after surgery, and then gradually restored to
normal level. However, CD4+CD25+CDl27low/−Treg cells in
complication group were initially more than those in experi-
mental group 1 month and 6 months after PSE, but they were
afterwards comparable. Furthermore, contents of immunoglob-
ulins (IgA, IgG and IgM) in the peripheral blood of patients from
three groups were comparable at all detection times. Our results
indicated that PSE had little impact on immune function of
cirrhosis patients with hypersplenism, which was consist with
previous studies [18].
In conclusion, PSE only has a short-term impact on the im-
mune function of cirrhosis patients with hypersplenism, whose
immune function can restore to the normal level in the long term,
even patients with complications. We also suggest that in early
stage of post-PSE, preventing infection and improving immune
function of patients are necessary so as to reduce complication
incidence.
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